[18F]-FDG PET analysis in gemcitabine/refametinib treated GEM. (a) Schematic representation of treatment and imaging plan for gemcitabine/vehicle and refametinib/vehicle treated CKP mice. Animals were weekly scanned and once the tumor reached the size of 200 mm3 or bigger, animals were enrolled into the study. (b) Exemplary presentation of PET analysis: T2w and corresponding PET (fused) images before and after the therapy demonstrating presence of two tumors with different [18F]-FDG uptake in the same animal (one delineated with red and another delineated with green line). Same tumor was followed pre- and post-therapy and SUV values were calculated (right graph). (c) Decrease in SUV mean values observed upon short-term gemcitabine and refametinib treatment. One line presents one tumor followed before and after therapy. Vehicle p = 0,46; gemcitabine p = 0,0013; vehicle p = 0,03; refametinib p = 0,0007.